Company Focus

Icon

Latest Icon News

Survey shows varied views on impact of new cancer drugs
Pharmaceutical
As the world’s leading cancer research professionals arrived at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona on Friday, they were given a reminder of some of the remaining challenges that lie ahead in their field.   13 September 2024


Insights

Company Spotlight

Latest News & Features of interest to Icon

Latest In Brief for Icon

Biotechnology
Following the negative results of the COAST Phase III trial announced on 24 March, Australia-based Opthea announced has updated on its clinical program, including the termination of COAST (Combination of OPT-302 with Aflibercept Study) and accelerated top-line results from its second Phase III trial ShORe (Study of OPT-302 in combination with Ranibizumab) in patients with wet AMD.   31 March 2025

Latest Relevant Ones To Watch News

Relevant Ones to Watch Companies

Reset all filters
Refine Search